Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 21;23(9):1507–1518. doi: 10.1038/mt.2015.104

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

TALEN treatment of primary T cells enables simultaneous and highly efficient processing of TRAC and dCK genes. (a) Overall gene architectures of dCK and TRAC open reading frames. Exons (dark blue) and introns (light blue) are indicated. dCK and TRAC TALEN targets are displayed and underlined. The TALEN binding sites and spacer sequences are respectively displayed in upper and lower cases letters. (b) Genotypic characterization of TALEN-mediated inactivation of dCK and TRAC genes by high throughput DNA sequencing. T cells treated with dCK and TRAC TALEN were allowed to grow for 6 days, their genomic DNA was extracted, amplified using TRAC or dCK specific PCR amplicons and analyzed by high throughput DNA sequencing. The frequencies of indels generated at TRAC and dCK locus are indicated.